Menu Search
Equities

Viatris Inc

VTRS:NSQ

Viatris Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.90
  • Today's Change0.08 / 0.68%
  • Shares traded6.42m
  • 1 Year change+21.18%
  • Beta0.9324
Data delayed at least 15 minutes, as of Sep 18 2024 21:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy2
Outperform2
Hold5
Sell2
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for Viatris Inc have a median target of 12.59, with a high estimate of 35.00 and a low estimate of 11.00. The median estimate represents a 5.80% increase from the last price of 11.90.
High194.1%35.00
Med5.8%12.59
Low-7.6%11.00

Dividends in USD

In 2023, Viatris Inc reported a dividend of 0.48 USD, equaling last years dividend. The 4 analysts covering the company expect dividends of 0.40 USD for the upcoming fiscal year, a decrease of 16.67%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in USD

On Aug 08, 2024, Viatris Inc reported 2nd quarter 2024 earnings of 0.69 per share. This result was in line with the consensus of the 6 analysts following the company and under-performed last year's 2nd quarter results by 8.00%.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate-1.28%
Viatris Inc reported annual 2023 earnings of 2.93 per share on Feb 28, 2024.
Average growth rate-9.74%
More ▼

Revenue history & estimates in USD

Mylan, Inc. had 2nd quarter 2024 revenues of 3.80bn. This bettered the 3.78bn consensus of the 6 analysts covering the company. This was 1.81% above the prior year's 2nd quarter results.
Average growth rate-0.74%
Mylan, Inc. had revenues for the full year 2023 of 15.43bn. This was 4.88% below the prior year's results.
Average growth rate+9.85%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.